Full-Time
Principal Scientist
Molecular Pathology and Imaging
Posted on 4/27/2024
Develops genetic medicines with non-viral systems
Biotechnology
Senior
Cambridge, MA, USA
Required Skills
Communications
Requirements
- PhD with minimum of 6 years of related experience, Master’s with a minimum of 10 years related experience, Bachelor’s with a minimum of 12 years related experience
- Minimum of 2 years of histology lab-based work experience required
- Industry experience preferred
- Experience in viral/non-viral gene therapy is highly desired
- Highly proficient in Super-resolution imaging, confocal microscopy, fluorescent imaging techniques, Molecular pathology techniques such as immunohistochemistry (IHC), immunofluorescence (IF/FISH), in situ hybridization (ISH, FISH), Image analysis software packages such as Infirm, ImageJ, Halo, Histological techniques including Sectioning (FFPE/Frozen) and H&E staining
- Familiarity with state-of-the-art imaging technologies such as single-molecule imaging, hyperspectral imaging, and super-resolution imaging desirable
- Proactive thinking and ability to multi-task to support multiple projects simultaneously
- Ability to work in a highly collaborative, team-based environment
- Excellent written and verbal communication skills
Responsibilities
- Inform scientific strategy for non-viral vector-based delivery platform using imaging data
- Single point of contact with shared accountability for execution and delivery of imaging data. As an SME analyze and interpret imaging data and present findings in both written and oral formats to cross-functional teams and other stakeholders
- Perform qualitative and quantitative image analyses
- Maintain awareness of relevant scientific advances in molecular imaging and pathology and apply cutting edge, new approaches where appropriate
- Supervise a small team with at least 1 direct report
- Develop, evaluate, design, and perform routine and complex immunohistochemistry (IHC), immunofluorescence (IF/FISH), in situ hybridization (ISH, FISH) and multiplex FISH/IHC assays on a variety of in vitro and in vivo samples
- Contribute to Improvement in the laboratory operational processes and establish standard operating protocols
- Interface externally with collaborators, and management of research performed by CRO(s)
Generation Bio is harnessing non-viral genetic medicine technologies to develop targeted treatments for a variety of diseases. Their unique ctLNP delivery system and innovative RES manufacturing process underscore their commitment to advancing genomic medicine with scalable solutions. This focus not only marks them as a leader in the biotechnology field but also creates a dynamic and technically stimulating environment that continually pushes the boundaries of genetic therapies.
Company Stage
IPO
Total Funding
$536.4M
Headquarters
Cambridge, Massachusetts
Founded
2016
Growth & Insights
Headcount